MA52951A - Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci - Google Patents
Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ciInfo
- Publication number
- MA52951A MA52951A MA052951A MA52951A MA52951A MA 52951 A MA52951 A MA 52951A MA 052951 A MA052951 A MA 052951A MA 52951 A MA52951 A MA 52951A MA 52951 A MA52951 A MA 52951A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- compositions
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688921P | 2018-06-22 | 2018-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52951A true MA52951A (fr) | 2021-04-28 |
Family
ID=67139695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052951A MA52951A (fr) | 2018-06-22 | 2019-06-24 | Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12275797B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3810194A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7513530B2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA52951A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019243636A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119285787A (zh) | 2017-03-31 | 2025-01-10 | 健玛保控股有限公司 | 双特异性抗cd37抗体、单克隆抗cd37抗体及其使用方法 |
| AR127743A1 (es) | 2021-09-06 | 2024-02-28 | Genmab Bv | Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos |
| CA3253038A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US6355271B1 (en) | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
| HUE038955T2 (hu) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
| EA015992B1 (ru) | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| PE20090499A1 (es) | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
| LT2544719T (lt) | 2010-03-12 | 2019-10-25 | Debiopharm Int Sa | Cd37 surišančios molekulės, ir jų imunokonjugatai |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| US20120189618A1 (en) | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| WO2012023053A2 (en) | 2010-08-16 | 2012-02-23 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| BR112013002167A2 (pt) | 2010-08-24 | 2016-05-31 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação |
| CN103068846B9 (zh) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | 包含二硫键稳定性Fv片段的双特异性抗体 |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| AU2012236210B2 (en) | 2011-04-01 | 2016-02-04 | Immunogen, Inc. | CD37-binding molecules and immunoconjugates thereof |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| DK2869845T3 (da) | 2012-07-06 | 2019-12-09 | Genmab Bv | Dimert protein med tredobbelte mutationer |
| WO2014006217A1 (en) * | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
| KR20150058236A (ko) | 2012-08-20 | 2015-05-28 | 글리크닉 인코포레이티드 | 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자 |
| MX387324B (es) | 2013-01-10 | 2025-03-18 | Genmab Bv | Variantes de regiones fc de igg1 de humano y usos de las mismas. |
| WO2015116729A2 (en) * | 2014-01-28 | 2015-08-06 | Emergent Product Development Seattle, Llc | Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders |
| JP2017513481A (ja) | 2014-04-16 | 2017-06-01 | ユーシービー バイオファルマ エスピーアールエル | 多量体Fcタンパク質 |
| CN119285787A (zh) | 2017-03-31 | 2025-01-10 | 健玛保控股有限公司 | 双特异性抗cd37抗体、单克隆抗cd37抗体及其使用方法 |
| AU2019354105A1 (en) | 2018-10-04 | 2021-04-29 | Genmab Holding B.V. | Pharmaceutical compositions comprising bispecific anti-CD37 antibodies |
-
2019
- 2019-06-24 JP JP2020571532A patent/JP7513530B2/ja active Active
- 2019-06-24 EP EP19735234.7A patent/EP3810194A1/en active Pending
- 2019-06-24 WO PCT/EP2019/066700 patent/WO2019243636A1/en not_active Ceased
- 2019-06-24 MA MA052951A patent/MA52951A/fr unknown
- 2019-06-24 US US17/253,276 patent/US12275797B2/en active Active
-
2024
- 2024-06-27 JP JP2024103927A patent/JP2024129084A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021528439A (ja) | 2021-10-21 |
| US20210371539A1 (en) | 2021-12-02 |
| EP3810194A1 (en) | 2021-04-28 |
| WO2019243636A1 (en) | 2019-12-26 |
| JP7513530B2 (ja) | 2024-07-09 |
| JP2024129084A (ja) | 2024-09-26 |
| US12275797B2 (en) | 2025-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54952A (fr) | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci | |
| FR24C1050I1 (fr) | Récepteurs d'antigènes chimériques basés sur des anticorps à domaine unique et leurs méthodes d'utilisation | |
| IL272367A (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
| EP3618871A4 (en) | FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES | |
| MA48462A (fr) | Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation | |
| MA48579A (fr) | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci | |
| EP3641768A4 (en) | CHIMERIC ANTIGEN RECEPTORS (CARS); COMPOSITIONS AND METHOD OF USE THEREOF | |
| MA43018B1 (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
| MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
| MA43365A (fr) | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci | |
| MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
| MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
| EP3399985A4 (en) | COMPOSITIONS AND LIBRARIES WITH RECOMBINANT T-CELL RECEPTORS AND METHOD FOR USING RECOMBINANT T-CELL RECEPTORS | |
| MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
| EP3383431A4 (en) | ANTI-GITR ANTIBODIES AND METHOD OF USE THEREOF | |
| EP3511346A4 (en) | BIFUNCTIONAL ANTI-CTLA4 AND ANTI-PD-1 ANTIBODIES, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | |
| EP3386536A4 (en) | COMPOSITION OF ANTIBODY CONSTRUCT AGONIST CONJUGATES AND METHOD FOR USE THEREOF | |
| EP3383430A4 (en) | ANTIBODIES AND METHOD FOR USE THEREOF | |
| MA39803A (fr) | Anticorps hémagglutinine dirigés contre le virus de la grippe b et méthodes d'utilisation | |
| MA44391A (fr) | Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20 | |
| MA71468A (fr) | Compositions et méthodes pour diminuer l'expression de tau | |
| BR112021016056A2 (pt) | Anticorpos de claudina 6 e usos dos mesmos | |
| EP3525583A4 (en) | ANTI-CS1 ANTIBODIES AND METHOD FOR USE THEREOF | |
| EP3893931A4 (en) | METHODS FOR USE OF ANTI-TREM2 ANTIBODIES | |
| EP3684819A4 (en) | Anti-ykl40 antibodies and methods of use |